BEAM – beam therapeutics inc. (US:NYSE)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

BEAM

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/2

10:17 am

beam

Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years [Yahoo! Finance]

Low Report

Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years [Yahoo! Finance]

Report

4/1

06:58 pm

beam

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine [Yahoo! Finance]

Low Report

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine [Yahoo! Finance]

Report

4/1

05:12 pm

beam

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Low Report

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Report

3/27

01:00 pm

beam

How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding [Yahoo! Finance]

Neutral Report

How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding [Yahoo! Finance]

Report

3/26

11:52 am

beam

Beam Therapeutics (BEAM) had its price target raised by Citigroup Inc. from $64.00 to $68.00. They now have a "buy" rating on the stock.

Low Report

Beam Therapeutics (BEAM) had its price target raised by Citigroup Inc. from $64.00 to $68.00. They now have a "buy" rating on the stock.

Report

3/25

07:00 am

beam

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Medium Report

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Report

2/28

02:39 am

beam

RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why [Yahoo! Finance]

Low Report

RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why [Yahoo! Finance]

Report

2/25

10:24 am

beam

Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.

Medium Report

Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.

Report

Date

Time

Symbol

Company Name

Action

%Chg

2/24/2026

07:01 am

beam

beam therapeutics inc.

BEAT Report

9.3%

beam therapeutics inc.

Report

11/4/2025

07:00 am

beam

beam therapeutics inc.

MISS Report

-3.7%

beam therapeutics inc.

Report

8/5/2025

07:00 am

beam

beam therapeutics inc.

BEAT Report

-2.1%

beam therapeutics inc.

Report

5/6/2025

07:00 am

beam

beam therapeutics inc.

MISS Report

-18.6%

beam therapeutics inc.

Report

Date

Time

Action

From

Firm

Impact

%Chg

3/26

11:34 am

Maintains

Buy

Citigroup

Low

Report

-0.2%

Report

3/26

11:34 am

Maintains

Buy

Citigroup

Low

Report

-0.2%

Report

2/25

10:10 am

Maintains

Sector Perform

RBC Capital

High

Report

-10.1%

Report

2/25

10:10 am

Maintains

Sector Perform

RBC Capital

High

Report

-10.1%

Report

2/25

08:23 am

Maintains

Outperform

Wedbush

Medium

Report

-9.4%

Report

2/25

08:23 am

Maintains

Outperform

Wedbush

Medium

Report

-9.4%

Report

2/20

03:50 pm

Initiates

Buy

Canaccord Genuity

Low

Report

0.3%

Report

2/20

06:51 am

Initiates

BUY

CANACCORD

Medium

Report

-3.2%

Report

Date

Time

Symbol

Headline

Impact

4/2

05:27 pm

beam

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Bellon Christine

Medium Report

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Bellon Christine

Report

4/2

05:22 pm

beam

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Cavanagh Bethany J

Medium Report

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Cavanagh Bethany J

Report

4/2

05:17 pm

beam

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Simon Amy

Medium Report

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Simon Amy

Report

4/2

05:16 pm

beam

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Emany Sravan Kumar

Medium Report

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Emany Sravan Kumar

Report

4/2

05:16 pm

beam

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Ciaramella Giuseppe

Medium Report

Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Ciaramella Giuseppe

Report

4/1

06:32 pm

beam

Form 4 Beam Therapeutics Inc. For: Mar 30 Filed by: Evans John M.

Low Report

Form 4 Beam Therapeutics Inc. For: Mar 30 Filed by: Evans John M.

Report

3/31

04:33 pm

beam

Form 144 Beam Therapeutics Inc. Filed by: Bellon Christine

Low Report

Form 144 Beam Therapeutics Inc. Filed by: Bellon Christine

Report

3/31

04:29 pm

beam

Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe

Low Report

Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.